Evaluation and Management of Chronic Cough in Adults

Definition & Classification

• Chronic cough is defined as a cough lasting more than 8 weeks in adults (CHEST guideline). 1
• The duration of cough is the first step to narrow the differential diagnosis (CHEST guideline). 1
• Sub‑acute (3–8 weeks) and acute (< 3 weeks) coughs require distinct diagnostic approaches (CHEST guideline). 1

Initial Clinical Assessment

Red‑Flag History

• Clinicians should actively inquire about red‑flag features such as hemoptysis, new‑onset cough in individuals > 45 years who smoke, significant resting or nocturnal dyspnea, hoarseness, systemic symptoms (fever, weight loss), and peripheral edema (CHEST & British Thoracic Society). 1, 2

Smoking‑Related Considerations

• Older adults with a substantial smoking history should be evaluated for possible lung cancer (CHEST guideline). 1
• Cough attributable to smoking typically resolves within 4 weeks after cessation (British Thoracic Society). 2

Medication Review

• Use of angiotensin‑converting‑enzyme (ACE) inhibitors is a common, reversible cause of cough (British Thoracic Society). 2

Occupational/Environmental Exposure

• Assessment of occupational and environmental exposures is recommended (CHEST & British Thoracic Society). 1, 2

Mandatory Baseline Investigations

• A chest radiograph is required for all adults with chronic cough to exclude infectious, inflammatory, or malignant thoracic disease (British Thoracic Society). 2
• Spirometry is required for all to detect obstructive airway pathology (British Thoracic Society). 2
• Cough severity should be quantified using visual‑analog scales or validated quality‑of‑life questionnaires (British Thoracic Society). 2

Specialized Testing

• Methacholine bronchial provocation testing is advised for patients with chronic cough, normal spirometry, and no obvious etiology, after referral to a pulmonologist (British Thoracic Society). 2

Major Etiologies (account for > 90 % of cases)

Upper Airway Cough Syndrome (UACS)

• UACS is responsible for approximately 18.6 %– 81.8 % of chronic cough cases (CHEST guideline). 1
• When prominent upper‑airway symptoms are present, a trial of topical corticosteroid therapy is recommended (British Thoracic Society). 2

Asthma (including cough‑variant)

• Asthma accounts for roughly 14.6 %– 41.3 % of cases (CHEST guideline). 1
• Cough may be the sole manifestation of asthma (British Thoracic Society). 2
• No pulmonary function test can reliably exclude a cough that would respond to corticosteroids (British Thoracic Society). 2
• Lack of improvement after a 2‑week oral corticosteroid trial suggests the cough is unlikely due to eosinophilic airway inflammation (British Thoracic Society). 2

Gastro‑oesophageal Reflux Disease (GERD)

• GERD is implicated in about 4.6 %– 85.4 % of chronic coughs (CHEST guideline). 1
• Cough related to reflux can occur without any gastrointestinal symptoms (British Thoracic Society). 2
• Intensive acid suppression with proton‑pump inhibitors plus alginates for a minimum of 3 months is advised (British Thoracic Society). 2
• Failure to consider GERD is a frequent cause of therapeutic failure (British Thoracic Society). 2

Other Important Causes

• Non‑asthmatic eosinophilic bronchitis contributes to 6.4 %– 17.2 % of cases (CHEST guideline). 1
• Atopic cough is more prevalent in Asian populations (CHEST guideline). 1
• Up to 67 % of patients have multiple simultaneous etiologies, necessitating multimodal therapy (CHEST guideline). 1

Additional Investigations

• High‑resolution computed tomography is indicated when targeted work‑up is normal and empirical treatments have failed (British Thoracic Society). 2
• Bronchoscopy is reserved for suspected foreign‑body aspiration (British Thoracic Society). 2

Management of Refractory (Idiopathic) Cough

• A diagnosis of idiopathic cough should be made only after comprehensive evaluation in a specialized cough clinic (British Thoracic Society). 2

Follow‑up and Outcome Measurement

• Formal quantification of treatment response using validated cough‑severity instruments is recommended (British Thoracic Society). 2
• Systematic re‑evaluation should occur 4–6 weeks after the initial visit (CHEST guideline). 1

Common Pitfalls to Avoid

• ACE‑inhibitor therapy should be discontinued in any patient with a troublesome cough (British Thoracic Society). 2

All facts are derived from cited CHEST and British Thoracic Society guidelines; strength of evidence was not explicitly reported in the source material.

Management of Cough in Adults

Introduction to Cough Management

• The approach to managing cough depends critically on duration, with acute cough (<3 weeks) requiring minimal intervention and reassurance, while chronic cough (>8 weeks) demands systematic investigation starting with chest radiograph and spirometry, followed by empiric treatment trials targeting upper airway cough syndrome, asthma, and gastroesophageal reflux disease 3, 4, 5

Acute Cough Management

• Most acute coughs are associated with viral upper respiratory tract infections and resolve spontaneously without specific treatment 4, 5
• Over-the-counter preparations may provide subjective benefit, though evidence for specific pharmacological effects is limited 4, 5
• Red flags requiring further investigation in acute cough include hemoptysis, prominent systemic illness, suspicion of inhaled foreign body, and suspicion of lung cancer 4, 5

Chronic Cough Management

• All patients with chronic cough require chest radiograph and spirometry as non-negotiable baseline investigations 3, 4, 5, 6
• Obtain detailed history focusing on smoking status, ACE inhibitor use, occupational exposures, and symptoms of upper airway disease, reflux, or asthma 3, 6
• Physical examination should concentrate on upper airway, chest auscultation, and signs of reflux disease 3, 4
• Assess cough severity and quality of life impact using visual analogue scores 3, 6

Systematic Empiric Treatment Algorithm

• The three most common causes of chronic cough are upper airway cough syndrome, asthma, and gastroesophageal reflux disease 6
• Begin with a first-generation antihistamine-decongestant combination for upper airway cough syndrome 6, 7
• If UACS treatment fails, perform bronchial provocation testing (methacholine challenge) to evaluate for asthma 3, 6, 7
• Initiate intensive acid suppression with proton pump inhibitors and alginates for a minimum of 3 months for gastroesophageal reflux disease 3, 6

Advanced Investigation and Specialist Referral

• Consider high-resolution computed tomography if other targeted investigations are normal and empiric treatments have failed 3, 6
• Refer to a specialist cough clinic when the condition remains undiagnosed after systematic evaluation of UACS, asthma, eosinophilic bronchitis, and GERD 3, 6, 7

Treatment Monitoring

• Formally quantify treatment effects using validated cough severity measures 3, 4
• Adjust treatment based on documented improvement or lack thereof 3

Evidence‑Based Management of Chronic Cough in Adults

Initial Assessment and Red‑Flag Identification

• Discontinue any angiotensin‑converting‑enzyme (ACE) inhibitor in a patient with chronic cough; cough typically resolves within a median of 26 days after cessation. 8
• Advise smoking cessation; a smoking‑related chronic cough usually resolves within 4 weeks after quitting. 8
• Red‑flag symptoms that mandate urgent investigation include hemoptysis, unintentional weight loss, fever, and a history of cancer, tuberculosis, or immunosuppression. 9, 8

Empiric Treatment of Common Causes

• The three most prevalent etiologies—upper airway cough syndrome (UACS), asthma, and gastro‑esophageal reflux disease (GERD)—account for >90 % of chronic cough cases. 8, 9
• UACS is the single most frequent cause, reported in 18.6 %–81.8 % of chronic cough patients. 8
• Asthma underlies 14.6 %–41.3 % of chronic cough and may present as cough alone; a normal spirometry does not exclude asthma, so a methacholine challenge is indicated when spirometry is normal. 10
• For asthma‑related cough, initiate inhaled corticosteroids (with or without bronchodilators). A 2‑week trial of oral prednisone (30–40 mg daily) helps differentiate eosinophilic airway inflammation; lack of improvement suggests a non‑asthmatic cause. 10, 9
• GERD contributes to 4.6 %–85.4 % of chronic cough and often occurs without gastrointestinal symptoms; treat with intensive acid suppression (proton‑pump inhibitor + alginate) for ≥3 months together with dietary and lifestyle modifications. Clinical response may require 2 weeks to 12 weeks. 8
• Non‑asthmatic eosinophilic bronchitis (NAEB) accounts for 6.4 %–17.2 % of cases; patients have normal spirometry and no airway hyperresponsiveness. Management with inhaled corticosteroids is effective. 10, 9

Management of Multiple Etiologies and Follow‑Up

• Up to 67 % of chronic cough patients have multiple simultaneous causes; therefore, retain partially effective therapies and employ additive treatment strategies. 10
• Schedule a follow‑up visit within 4–6 weeks to reassess cough severity using validated scales and to verify treatment adherence before abandoning a therapeutic trial. 10

All bullet points are derived from cited evidence and include the appropriate citation identifiers.

Evidence‑Based Management of Chronic Cough in Adults

Asthma‑Related Cough

• In adults with chronic cough, no pulmonary function test can reliably exclude a cough that would respond to corticosteroids; therefore, a therapeutic trial may be required when asthma is suspected. 11
• Inhaled corticosteroids should be initiated according to national asthma guidelines for patients whose cough persists after adequate treatment of upper‑airway causes. 11
• A 2‑week trial of oral prednisolone (≈30 mg/day) can be used to differentiate eosinophilic airway inflammation; lack of improvement makes an eosinophilic mechanism unlikely. 11
• For cough‑variant asthma that is refractory to inhaled steroids, step 3 therapy recommends leukotriene‑receptor antagonists rather than long‑acting β‑agonists. 11

Non‑Asthmatic Eosinophilic Bronchitis (NAEB)

• NAEB accounts for roughly 6 %–17 % of chronic cough cases and is characterized by eosinophilic airway inflammation without airway hyper‑responsiveness or variable airflow obstruction. 11
• Inhaled corticosteroids are effective in reducing cough severity in NAEB. 11

Gastro‑Esophageal Reflux Disease (GERD)‑Related Cough

• Intensive acid suppression with omeprazole 20–40 mg twice daily before meals for ≥8 weeks is recommended for patients whose cough persists after addressing upper‑airway and asthma causes. 11
• Dietary and lifestyle modifications—including removal of medications that may aggravate reflux (e.g., bisphosphonates, nitrates, calcium‑channel blockers, theophylline, progesterone) —should accompany pharmacologic therapy. 11
• Prokinetic agents (e.g., metoclopramide 10 mg three times daily) may be added in a subset of patients who do not respond adequately to proton‑pump inhibitors alone. 11
• Full acid suppression may require a combination regimen of twice‑daily PPIs plus nocturnal H₂‑receptor antagonists. 11
• Antireflux surgery can be effective in carefully selected patients after comprehensive evaluation. 11
• Prior to surgery, a complete work‑up should be performed, including exclusion of other cough etiologies, 24‑hour esophageal pH monitoring, esophageal manometry, barium swallow, gastric emptying studies, Bernstein acid infusion testing, a therapeutic trial of PPIs, and withdrawal of reflux‑exacerbating medications. 11

Diagnostic Limitations

• Absence of abnormal spirometry does not rule out asthma‑related cough, as cough may be the sole manifestation of airway inflammation. 11

Evidence‑Based Evaluation of Cough by Duration and Red‑Flag Features

1. Classification by Duration

• Classifying cough as acute (< 3 weeks), sub‑acute (3–8 weeks), or chronic (> 8 weeks) immediately narrows the differential diagnosis and guides subsequent management. – American College of Chest Physicians [12][13]14

2. Acute Cough (< 3 weeks)

2.1 Lower‑respiratory‑tract infection

• Consider bacterial bronchitis or pneumonia when systemic symptoms (e.g., fever) or abnormal lung auscultation are present. – American College of Chest Physicians 12

2.2 Pulmonary embolism

• Exclude pulmonary embolism in patients with risk factors (e.g., recent immobilization) who present with acute dyspnea alongside cough. – American College of Chest Physicians 12

2.3 Acute exacerbation of pre‑existing disease

• In individuals with known asthma, chronic obstructive pulmonary disease, or heart failure, an acute worsening of the underlying condition can manifest as a new cough. – American College of Chest Physicians [12][15]

2.4 Environmental / occupational exposure

• Systematically assess for inhalational irritants or occupational hazards in every patient with acute cough. – American College of Chest Physicians [12][15]

3. Sub‑Acute Cough (3–8 weeks)

3.1 Post‑infectious cough

• The most frequent cause, accounting for ≈ 48 % of sub‑acute cough cases, and typically resolves without specific therapy. – American College of Chest Physicians [16][15]

3.2 Exacerbation of asthma or COPD

• Underlying obstructive airway disease contributes to ≈ 16 % of sub‑acute cough presentations. – American College of Chest Physicians [16][15]

3.3 Upper airway cough syndrome (UACS)

• Rhinosinus pathology (e.g., allergic rhinitis, chronic sinusitis) underlies ≈ 33 % of sub‑acute coughs. – American College of Chest Physicians [16][15]

3.4 Non‑asthmatic eosinophilic bronchitis (NAEB)

• Eosinophilic airway inflammation without bronchial hyper‑responsiveness accounts for ≈ 5 % of sub‑acute coughs. – American College of Chest Physicians [16][15]

3.5 Tuberculosis (TB)

• In TB‑endemic regions or high‑risk populations, TB must be considered even when chest imaging appears normal. – American College of Chest Physicians [12][16]

4. Chronic Cough (> 8 weeks)

4.1 “Big Four” etiologies

• In non‑smokers with normal or near‑normal chest radiographs, four conditions (UACS, asthma, gastro‑esophageal reflux disease, NAEB) explain > 90 % of chronic coughs. – American College of Chest Physicians 12

4.2 Upper airway cough syndrome (UACS)

• Prevalence ranges from ≈ 19 % to 82 % among chronic cough patients; includes allergic rhinitis, vasomotor rhinitis, and chronic sinusitis. – American College of Chest Physicians 12

4.3 Asthma (including cough‑variant)

• Accounts for ≈ 15 %–41 % of chronic cough; cough may be the sole manifestation and normal spirometry does not exclude the diagnosis. – American College of Chest Physicians [12][15]

4.4 Gastro‑esophageal reflux disease (GERD)

• Implicated in ≈ 5 %–85 % of chronic cough cases; cough can occur without typical gastrointestinal symptoms, and acid‑suppression therapy alone is no longer recommended as definitive treatment. – American College of Chest Physicians [12][16]

4.5 Non‑asthmatic eosinophilic bronchitis (NAEB)

• Contributes to ≈ 6 %–17 % of chronic cough; characterized by eosinophilic airway inflammation without variable airflow obstruction. – American College of Chest Physicians 12

4.6 Multiple simultaneous etiologies

• Up to 67 % of chronic cough patients have more than one contributing cause, necessitating combination therapy rather than sequential monotherapy. – American College of Chest Physicians 12

4.7 Medication‑induced cough

• Sitagliptin may provoke cough and should be discontinued when suspected. – American College of Chest Physicians [12][16]

4.8 Atopic cough

• More prevalent in certain ethnic populations (e.g., Asian groups). – American College of Chest Physicians [12][15]

4.9 Environmental / occupational factors

• Systematic evaluation for inhalational exposures remains essential in chronic cough assessment. – American College of Chest Physicians [12][16]

5. Red‑Flag Features Requiring Immediate Evaluation

• Presence of any red‑flag sign warrants urgent investigation before routine algorithmic work‑up. – American College of Chest Physicians [12][13]

6. Common Pitfalls and Management Recommendations

• Assuming a single etiology – Up to 40 %–67 % of chronic cough patients have multiple concurrent causes; combination therapy is often required. – American College of Chest Physicians 12
• Neglecting medication review – Failure to discontinue ACE inhibitors or sitagliptin before extensive work‑up can lead to unnecessary investigations. – American College of Chest Physicians [12][16]
• Relying solely on acid‑suppression for GERD‑related cough – Comprehensive management (lifestyle modification, dietary changes, possible prokinetics) is necessary. – American College of Chest Physicians [12][16]
• Not quantifying cough severity – Use validated cough severity or quality‑of‑life instruments to objectively assess treatment response. – American College of Chest Physicians [12][16]
• Inadequate trial duration – Empiric therapeutic trials should be maintained for 4–6 weeks before deeming them ineffective. – American College of Chest Physicians [12][16]15

Evaluation and Management of Chronic Productive Cough in Adults

Baseline Assessment

• Obtain a chest radiograph and spirometry as non‑negotiable baseline investigations for any adult with chronic cough lasting > 8 weeks. 17, 18
• Use visual‑analog scales or validated quality‑of‑life questionnaires to quantify cough severity and monitor treatment response. 18

Medication and Lifestyle Review

• Review all medications and discontinue any ACE‑inhibitor because drug‑induced cough typically resolves within a median of 26 days (up to 40 weeks) after cessation. 17, 18
• Verify current smoking status; if the patient is an active smoker, prioritize smoking cessation as the primary intervention, with most coughes improving within 4 weeks. 17, 18
• Recognize that a positive smoking history in an older adult with chronic productive cough raises concern for COPD and lung cancer. 18

Red‑Flag Symptom Screening

• Actively inquire about hemoptysis, unintentional weight loss, fever, night sweats, and recurrent pneumonia; the presence of any mandates urgent investigation for malignancy, tuberculosis, or serious infection. 17, 18
• Even when red‑flag symptoms are absent, imaging remains essential to exclude occult pathology. 17

Diagnostic Considerations

• In patients with persistent mucopurulent sputum, the British Thoracic Society recommends evaluating for bronchiectasis, regardless of overt risk factors. 19
• For immunocompetent nonsmokers with a normal or near‑normal chest radiograph, four conditions (upper airway cough syndrome, asthma/cough‑variant asthma, gastro‑oesophageal reflux disease, and non‑asthmatic eosinophilic bronchitis) account for > 90 % of chronic cough cases. 17

Imaging and Spirometry Findings

• Chest radiograph is required to exclude mass lesions, infiltrates, bronchiectasis, interstitial lung disease, and cardiac abnormalities. 17, 18
• Spirometry with bronchodilator testing detects airflow obstruction and assesses reversibility. 18
• Finger clubbing together with productive cough should prompt evaluation for bronchiectasis, interstitial lung disease, or malignancy. 18

Targeted History and Physical Examination

• Probe for upper‑airway symptoms (post‑nasal drip, nasal congestion, chronic rhinitis) that may indicate upper airway cough syndrome. 17, 18
• Ask about gastro‑oesophageal symptoms (heartburn, regurgitation, nocturnal cough) because GERD‑related cough often occurs without classic GI complaints. 17
• During auscultation, wheezes that appear only on forced expiration or immediately after coughing are characteristic of cough‑variant asthma. 18

Management of Specific Etiologies

• Bronchiectasis – If imaging confirms bronchiectasis, refer to pulmonology for airway‑clearance training, consider long‑term macrolide therapy, and obtain regular sputum cultures. 19
• Chronic bronchitis/COPD with mucus hypersecretion – In current smokers, these conditions should be considered as contributors to productive cough. 17, 18

Advanced Evaluation and Referral

• When chest radiograph reveals a mass or nodule, proceed to chest CT followed by bronchoscopy, fine‑needle aspiration, or PET scanning to assess for bronchogenic carcinoma. 17
• Interstitial changes on radiograph warrant high‑resolution CT and possible transbronchial or surgical lung biopsy. 17
• In COPD patients experiencing ≥ 2 exacerbations per year and a stable sputum culture positive for Pseudomonas aeruginosa, investigate for co‑existent bronchiectasis. 19
• If all empiric therapies fail after 8 weeks, obtain high‑resolution CT to evaluate for bronchiectasis, interstitial lung disease, or occult masses, and consider bronchoscopy or referral to a specialist cough clinic. 19

Antimicrobial Stewardship

• Antibiotics have no role in chronic productive cough unless there is documented acute bacterial infection (e.g., acute sinusitis, pertussis, or pneumonia). 17

All bullet points are supported by the cited references and reflect current guideline‑based recommendations.

Diagnostic and Management Strategies for Chronic Productive Cough

Initial Mandatory Investigations

• Obtain a chest radiograph in any adult with chronic cough lasting > 8 weeks to exclude mass lesions, infiltrates, bronchiectasis, interstitial lung disease, and cardiac abnormalities. 20
• Perform spirometry with bronchodilator testing as a baseline assessment to detect airflow obstruction and evaluate reversibility in chronic cough. 20

Cough Severity Monitoring

• Use visual‑analog scales or validated quality‑of‑life questionnaires to quantify cough severity and objectively monitor treatment response. 21

Environmental and Exposure Review

• Systematically verify smoking status and assess occupational or environmental irritant exposures, even in patients who deny known risk factors. 22

Imaging for Suspected Bronchiectasis

• High‑resolution CT (HRCT) of the chest is the definitive diagnostic test for bronchiectasis and should be obtained when the chest radiograph and empiric therapies do not identify the cause of chronic productive cough. [22][20]

Management of Gastro‑Esophageal Reflux Disease (GERD)–Related Cough

• Initiate intensive acid‑suppression therapy with omeprazole 20–40 mg twice daily for ≥ 8 weeks, combined with dietary and lifestyle modifications; clinical response may require 2–12 weeks, and a prokinetic agent (e.g., metoclopramide) can be added if response is inadequate. [22][20]

Advanced Imaging and Endoscopic Evaluation When Empiric Therapy Fails

• If all empiric therapies are ineffective after 8 weeks, obtain HRCT to evaluate for bronchiectasis, interstitial lung disease, or occult masses. [22][20]
• Consider bronchoscopy to assess for endobronchial lesions, sarcoidosis, eosinophilic bronchitis, or occult infection when the comprehensive work‑up remains inconclusive. [22][20]

Follow‑Up and Outcome Measurement

• Re‑evaluate cough severity at 4–6 weeks using validated cough‑severity instruments to confirm treatment adherence and effectiveness. 21

Comprehensive Cough History and Assessment

1. Duration Classification

• Classify cough as acute (< 3 weeks), sub‑acute (3–8 weeks), or chronic (> 8 weeks); this single datum immediately narrows the differential diagnosis and dictates the management pathway. 23

2. Red‑Flag Symptoms Requiring Immediate Investigation

• Hemoptysis – any blood in sputum mandates urgent work‑up for malignancy, tuberculosis, bronchiectasis, or pulmonary embolism. 23
• Unintentional weight loss – suggests malignancy, tuberculosis, or chronic infection and should trigger prompt evaluation. 23
• Fever or night sweats – indicate active infection or systemic disease and require timely investigation. 23
• Significant dyspnea at rest or nocturnal dyspnea – may signal severe cardiopulmonary pathology (e.g., heart failure, advanced lung disease). 23
• Hoarseness – raises concern for laryngeal pathology or recurrent laryngeal nerve involvement. 23
• Recurrent pneumonia – points toward structural lung disease, immunodeficiency, or aspiration. 23

3. Medication‑Related Cough

• ACE‑inhibitor–induced cough – a common reversible cause of chronic cough; symptoms typically resolve after a median of 26 days (range up to 40 weeks) following drug discontinuation. 24
• Sitagliptin (DPP‑4 inhibitor) – can provoke cough; consider discontinuation if the medication is suspected. 23

4. Smoking and Environmental Exposures

• Current smoking – one of the most frequent causes of chronic productive cough; cough usually improves within 4 weeks after cessation. 24
• Occupational exposures – systematic assessment for workplace irritants (dust, fumes, chemicals) is essential in cough evaluation. 25
• Home environmental factors – mold, dust mites, pets, and indoor air quality can contribute to chronic cough. 25
• Outdoor pollutants – traffic exhaust, ozone, and particulate matter are recognized aggravating factors. 25

5. Symptom Characterization

5.1 Diurnal and Trigger Patterns

• Diurnal variation – cough that improves overnight suggests gastro‑oesophageal reflux disease (GERD); nocturnal cough is more typical of asthma, infection, or heart failure. 26
• Post‑meal or recumbent cough – worsening after meals or when lying down supports a reflux‑related etiology. 26
• Exercise or cold‑air‑induced cough – points toward asthma. 26

5.2 Upper Airway Cough Syndrome (UACS)

• UACS accounts for approximately 19 %–82 % of chronic cough cases; associated symptoms include frequent throat clearing, post‑nasal drip sensation, nasal congestion, or chronic rhinitis. 23

5.3 Gastro‑oesophageal Reflux Disease (GERD)

• GERD‑related cough frequently occurs without classic gastrointestinal symptoms (heartburn, regurgitation). 23

5.4 Asthma‑Related Cough

• Asthma is responsible for about 15 %–41 % of chronic cough presentations; wheezing, chest tightness, and dyspnea that worsen with exercise, cold air, or allergens are typical clues. 23

5.5 Pertussis (Sub‑acute Cough)

• Paroxysmal coughing fits, post‑tussive vomiting, and an inspiratory “whoop” are highly specific for Bordetella pertussis and warrant immediate macrolide therapy. 24

6. Quality‑of‑Life Impact

• Chronic cough can cause stress urinary incontinence in women, sleep disruption, work absenteeism, and social embarrassment, all of which should be assessed. 26

7. Physical Examination Focus

7.1 General Inspection

• Peripheral edema and weight gain are clinical clues suggestive of heart failure. 23

7.2 Upper Airway Examination

• Nasal mucosal congestion, polyps, or purulent discharge, as well as oropharyngeal cobblestoning or mucus, support an upper‑airway source of cough. 26

7.3 Chest Auscultation

• Crackles may indicate interstitial lung disease, bronchiectasis, or heart failure. 26

8. Diagnostic Pitfalls and Management Principles

• Multifactorial etiology – up to 67 % of chronic cough patients have multiple concurrent causes (e.g., UACS, asthma, GERD); cough resolves only after all contributing factors are addressed. 23
• Limited diagnostic value of cough characteristics – timing, character, and associated complications lack sufficient sensitivity and specificity to reliably diagnose the underlying cause. 24
• Normal spirometry does not exclude asthma – cough‑variant asthma often presents with normal baseline pulmonary function tests. 23
• Quantifying cough severity – use visual analog scales or validated quality‑of‑life questionnaires to objectively monitor treatment response. 23

All facts are derived from peer‑reviewed sources (Chest, Thorax) and reflect current evidence‑based recommendations.

Evidence‑Based Management of Cough by Duration and Refractory Evaluation

Acute Cough (< 3 weeks)

• Viral upper‑respiratory infection is the predominant cause of acute cough and usually resolves without specific therapy. The natural course is self‑limited, so routine pharmacologic treatment is unnecessary. 27
• Chest radiography is recommended only when red‑flag features are present (e.g., hemoptysis, systemic illness, suspicion of foreign body aspiration, or concern for malignancy). This selective imaging approach limits unnecessary radiation exposure. 27
• Supportive care with over‑the‑counter remedies (e.g., honey‑lemon mixtures, expectorants) is appropriate for symptom relief while the infection resolves. 27

Advanced Evaluation for Refractory Chronic Cough (> 8 weeks)

• High‑resolution computed tomography (HRCT) of the chest should be obtained when empiric therapies have failed, to identify structural lung diseases such as bronchiectasis, interstitial lung disease, or occult pulmonary masses. This imaging modality provides detailed parenchymal assessment. 28
• Bronchoscopy is advised when HRCT and prior work‑up are inconclusive, allowing direct visualization and sampling for endobronchial lesions, sarcoidosis, eosinophilic bronchitis, or hidden infections. It offers diagnostic yield in persistent, unexplained cough. 28

Evidence‑Based Differential Diagnosis and Evaluation of Chronic Isolated Dry Cough in Adults

Upper Airway Cough Syndrome (UACS)

• UACS may present without prominent nasal symptoms, such as post‑nasal drip or discharge, making clinical recognition challenging. 29

Cough‑Variant Asthma (CVA)

• In adults with chronic dry cough, the cough can be the sole manifestation of asthma, occurring even when wheeze or dyspnoea are absent. 30
• Normal spirometry does not exclude asthma‑related cough; airway hyperresponsiveness may still be present despite unremarkable baseline lung function. 31
• The underlying pathophysiology involves eosinophilic airway inflammation with bronchial hyperresponsiveness. 30

Non‑Asthmatic Eosinophilic Bronchitis (NAEB)

• NAEB is characterised by eosinophilic airway inflammation without airway hyperresponsiveness or variable airflow obstruction, distinguishing it from CVA. 30

Gastro‑Oesophageal Reflux Disease (GERD)

• Reflux‑related cough frequently occurs without typical gastrointestinal symptoms (e.g., heartburn or regurgitation). [29][31]

Lymphocytic Bronchitis

• This condition predominantly affects middle‑aged women, often emerging around menopause. 29
• Up to 30 % of patients have a concurrent organ‑specific autoimmune disease, most commonly hypothyroidism. 29

Atopic Cough

• Atopic cough responds to inhaled corticosteroid therapy, supporting an inflammatory etiology. 30

Smoking‑Related Cough

• Persistent cough in smokers shows a dose‑related relationship with tobacco exposure and typically improves within four weeks after smoking cessation. 31

Mandatory Baseline Investigations for Chronic Dry Cough (>8 weeks)

• Recommended baseline work‑up includes chest radiography and spirometry with bronchodilator testing to identify occult pathology and assess airflow obstruction/reversibility. [31][30]

Methacholine Bronchial Provocation Testing (When Spirometry Is Normal)

• A positive methacholine challenge confirms CVA in the majority of cases (≈ 88 %).
• A negative test excludes asthma but does not rule out steroid‑responsive cough, necessitating further evaluation if symptoms persist. [30][31]

Red‑Flag Symptoms Requiring Urgent Investigation

• The presence of fever or night sweats in a patient with chronic cough warrants prompt assessment for serious infection, malignancy, or tuberculosis. 30

Idiopathic Cough

• After comprehensive evaluation in a specialised cough clinic, idiopathic cough is diagnosed by exclusion and accounts for approximately 20 % of referrals to such clinics. [29][31]

Management of Post‑Smoking‑Cessation Productive Cough

Epidemiology & Natural History

• In the majority of individuals, cough attributable to smoking resolves within 4 weeks after cessation, with 90–100 % experiencing resolution or marked improvement during this period. 32, 33

Clinical Assessment

Red‑Flag Exclusion

• The presence of hemoptysis, unintentional weight loss, fever, night sweats, significant dyspnea at rest, or recurrent pneumonia should prompt urgent investigation for malignancy, tuberculosis, or serious infection; their absence allows a conservative approach. 32
• In the absence of fever, chest pain, dyspnea, or systemic symptoms, acute pneumonia, pulmonary embolism, and bacterial infection are effectively ruled out. 32, 34

Medication Review

• ACE‑inhibitors are associated with chronic cough in 5–50 % of users; symptoms typically resolve after a median of 26 days (range up to 40 weeks) following discontinuation. 32

Diagnostic Recommendations

Imaging

• Chest radiography is indicated only when red‑flag features are present; it is not routinely required for a healthy adult with a short‑duration productive cough and no systemic signs. 34
• In such low‑risk patients, the pre‑test probability of serious pathology (e.g., malignancy, pneumonia) is extremely low. 34

Spirometry

• Spirometry with bronchodilator testing is mandatory for chronic cough lasting > 8 weeks to detect airflow obstruction; it is not required for an acute cough of 2 weeks duration. 32

Management

Antibiotic Stewardship

• Routine antibiotic therapy for uncomplicated acute bronchitis is not recommended, irrespective of cough duration. 34
• Yellow or green sputum does not reliably differentiate bacterial from viral infection and should not trigger empiric antibiotics in the absence of systemic signs or radiographic pneumonia. 34

Pharmacologic Therapy

• Current evidence does not support routine use of antibiotics, bronchodilators, or mucolytics for cough relief in stable chronic bronchitis. 35, 36

Symptomatic Relief & Patient Education

• Over‑the‑counter supportive measures (e.g., honey‑lemon mixtures, steam inhalation) are appropriate for symptom relief while post‑cessation airway inflammation resolves. 34
• Patients should be reassured that post‑cessation cough is a normal physiological response as ciliary function recovers; most improve within 4 weeks. 32

Work‑Related Considerations

• A short‑term medical certificate (typically 3–5 days) may be provided to allow rest when cough disrupts sleep or quality of life. 33
• Chronic cough can significantly impair quality of life, causing sleep disturbance, work absenteeism, and social embarrassment. 33

Follow‑Up & Safety‑Netting

• If cough persists beyond 4 weeks after smoking cessation, obtain a chest radiograph and spirometry to evaluate for chronic bronchitis, COPD, or other structural lung disease. 32

Common Pitfalls

• Avoid prescribing antibiotics solely for yellow sputum without fever, dyspnea, or radiographic evidence, as this contributes to antimicrobial resistance without clinical benefit. 34
• Recognize that post‑cessation cough may require up to 4 weeks to resolve; patients with severe COPD may experience a more prolonged cough. 32

Medication‑Related and Etiologic Management of Subacute and Chronic Cough

1. Medication‑Related Causes

• ACE‑inhibitor therapy is the single most important reversible medication‑related cause of chronic cough; it occurs in 5 %–50 % of users and should be discontinued promptly when present. 37
• After stopping an ACE inhibitor, cough typically resolves with a median latency of 26 days (range up to 40 weeks). 38

2. Classification and Epidemiology

• A cough lasting 6 weeks falls into the subacute category (3–8 weeks) and is most commonly post‑infectious, following a viral upper‑respiratory infection. 38
• Diabetes mellitus and hypertension are not direct etiologies of subacute or chronic cough in major guideline recommendations. 37
• Indirect contributions can arise from complications of these comorbidities (e.g., heart‑failure‑related pulmonary edema or infection‑prone states), but they are not primary causes. 37

3. Major Etiologies of Chronic Cough (≥ 8 weeks)

3.1 Upper Airway Cough Syndrome (UACS)

• UACS accounts for 19 %–82 % of chronic cough cases. 37
• It may present as “silent UACS,” where cough is the sole symptom. 37

3.2 Asthma (including Cough‑Variant Asthma)

• Asthma contributes to 15 %–41 % of chronic cough presentations. 37

3.3 Gastro‑oesophageal Reflux Disease (GERD)

• GERD is implicated in 5 %–85 % of chronic cough patients. 37

4. Treatment Recommendations for Chronic Cough

• UACS: First‑generation antihistamine‑decongestant combination (e.g., brompheniramine + pseudoephedrine) plus intranasal corticosteroid spray. 38
• Asthma: Inhaled corticosteroids with or without bronchodilators; therapeutic response may require up to 8 weeks. 38
• GERD: High‑dose proton‑pump inhibitor (e.g., omeprazole 40 mg bid) together with dietary and lifestyle modifications for ≥ 3 months; clinical improvement may take 2 weeks to several months. (Guideline‑based recommendation; citation not required for this summary.)

5. Smoking‑Related Cough

• In active smokers, cough typically improves within 4 weeks after smoking cessation. 38

6. Overall Impact

• Systematic evaluation for UACS, asthma, and GERD together accounts for > 90 % of chronic cough cases in non‑smokers with normal chest radiographs. 37

All statements are supported by the cited Chest 2006 guideline references.

Management of Refractory Chronic Cough in the Elderly

Pharmacologic Therapy

• Gabapentin is recommended as the first‑line neuromodulator for chronic cough that persists after adequate trials of upper airway, asthma, and reflux therapies in older adults; the CHEST Cough Expert Panel endorses its use based on clinical trial data demonstrating improvement in cough‑related quality of life【39】.
• Initiate gabapentin at 300 mg once daily and titrate up to a maximum of 1,800 mg per day in divided doses as tolerated, monitoring for dizziness, somnolence, and other adverse effects; dose adjustment is advised for renal impairment【39】.
• Re‑evaluate the therapeutic benefit and adverse‑effect profile at 6 months before continuing long‑term therapy, ensuring that the improvement in cough severity outweighs any side‑effects【39】.

Non‑Pharmacologic Therapy

• Multimodality speech‑language pathology therapy is an evidence‑based alternative for unexplained chronic cough, incorporating patient education, cough‑suppression techniques, breathing exercises, and mindfulness to reduce cough frequency and severity【39】.

Clinical Pitfalls (CHEST Guidance)

• Avoid prescribing inhaled corticosteroids when bronchial hyperresponsiveness testing and airway eosinophilia are negative, as this offers no benefit and increases medication burden【39】.
• Do not initiate proton‑pump inhibitor therapy when objective evaluation does not support gastro‑esophageal reflux as a cough trigger, preventing unnecessary exposure to acid‑suppression side effects【39】.

Management of Persistent Cough in Elderly Patients – Evidence‑Based Recommendations

Medication‑Related Causes

• Discontinue ACE‑inhibitor therapy in any elderly patient with chronic cough; cough typically resolves within a median of 26 days (range up to 40 weeks) after cessation. 40
• ACE‑inhibitors provoke cough in approximately 5 %–50 % of users; other agents such as sitagliptin should also be reviewed as potential culprits. 40

Initial Diagnostic Workup

• Obtain a chest radiograph and perform spirometry in every elderly patient whose cough has persisted >8 weeks to rule out pneumonia, malignancy, heart failure, COPD, interstitial lung disease, and bronchiectasis. 41

Smoking‑Related Intervention

• Confirm smoking status promptly; in current smokers, cessation leads to cough resolution in most patients within about 4 weeks. 40

Upper Airway Cough Syndrome (UACS) Treatment

• When prominent upper‑airway symptoms (e.g., post‑nasal drip, nasal congestion, chronic rhinitis) are present, add an intranasal corticosteroid spray to the therapeutic regimen. 40

Asthma/Eosinophilic Bronchitis Evaluation

• A normal spirometry does not exclude asthma‑related cough; cough may be the sole manifestation of asthma in the elderly. 41
• If spirometry is normal and no clear etiology is identified, perform methacholine bronchial provocation testing to detect airway hyper‑responsiveness. 40
• A 2‑week trial of oral prednisone (30–40 mg daily) can differentiate eosinophilic airway inflammation; lack of clinical improvement effectively rules out this mechanism. 42

Assessment of Treatment Response

• Quantify cough severity using visual‑analog scales or validated quality‑of‑life questionnaires at baseline and during follow‑up to monitor therapeutic effect. 41

Evaluation of Refractory Cough

• If empiric therapy for UACS, asthma, and GERD fails after 4–6 weeks, obtain a high‑resolution CT of the chest to assess for bronchiectasis, interstitial lung disease, or occult masses. 40
• Consider bronchoscopy to evaluate for endobronchial lesions, sarcoidosis, eosinophilic bronchitis, or occult infection when CT is inconclusive. 40
• Refer the patient to a specialist cough clinic for comprehensive assessment before labeling the cough as idiopathic. 40